1. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies

   • Jeanne Tie
   • Jayesh Desai

   Review 15 August 2014 Pages: 179 - 188

   

2. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model

   • Olivier Trédan
   • Magali Lacroix-Triki
   • Philippe Barthélémy

   Review 05 September 2014 Pages: 189 - 198

   

3. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists

   • Jean-Baptiste Rey
   • Vincent Launay-Vacher
   • Christophe Tournigand

   Review Open access 12 September 2014 Pages: 199 - 213

4. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis

   • Hanno Niess
   • Peter Camaj
   • Christiane J. Bruns

   Original Research 22 June 2014 Pages: 215 - 227

   

5. Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports

   • Adeline Egron
   • Pascale Olivier-Abbal
   • Emmanuelle Bondon-Guitton

   Original Research 25 July 2014 Pages: 229 - 234

   

6. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

   • Donald L. Smith
   • Jaime Acquaviva
   • David A. Proia

   Original Research Open access 01 August 2014 Pages: 235 - 245

   

7. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC

   • Cecile Bosc
   • Gilbert R. Ferretti
   • Denis Moro-Sibilot

   Original Research 15 August 2014 Pages: 247 - 253

   

8. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial

   • David F. Heigener
   • José Rodrigues Pereira
   • Ulrich Gatzemeier

   Original Research 09 September 2014 Pages: 255 - 265

   

9. Decreased mRNA expression of GATA1 and GATA2 is associated with tumor aggressiveness and poor outcome in clear cell renal cell carcinoma

   • Inga Peters
   • Natalia Dubrowinskaja
   • Jürgen Serth

   Original Research 19 September 2014 Pages: 267 - 275

   

10. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

    • M. Donini
    • S. Buti
    • GOIRC (Italian Oncology Group for Clinical Research)

    Original Research 19 September 2014 Pages: 277 - 286

    

11. Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study

    • Jiaping Li
    • Fujun Zhang
    • Shi Ke

    Original Research 08 October 2014 Pages: 287 - 295

    

12. Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature

    • Isabel Ihnenfeld Arciénega
    • Patrick Imesch
    • Konstantin J. Dedes

    Day-to-Day Practice 17 December 2014 Pages: 297 - 301

    

13. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology

    • Sohita Dhillon

    Adis Drug Evaluation 19 April 2015 Pages: 303 - 310